公开(公告)号：US20230038503A1

公开(公告)日：2023-02-09

申请号：US17782797

申请日：2020-12-11

Applicant: UNIVERSITEIT ANTWERPEN

Inventor： Jonathan BAETS ,  Willem DE RIDDER

IPC: A61K31/519 ,  C12N15/113 ,  A61K31/4196 ,  A61K31/37 ,  A61K31/44 ,  A61K31/428 ,  A61K38/13 ,  A61K31/436 ,  A61K31/365 ,  A61K31/5375 ,  A61K39/395 ,  A61K31/56 ,  A61K45/06 ,  G01N33/68

Abstract: The invention concerns KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis, and diagnosis of these diseases based on KDM5A expression levels in muscle tissue. The invention further concerns pharmaceutical compositions comprising KDM5A inhibitors for use in prevention or treatment of idiopathic inflammatory myopathies such as polymyositis, dermatomyositis, necrotizing autoimmune myopathy, and in particular sporadic inclusion body myositis.